Deregulation of glycogen synthase kinase-3 (GSK-3) activity is believed to play a key role in
the pathogenesis of Alzheimer's disease (AD). GSK-3 activity is regulated by …

Glycogen synthase kinase-3 (GSK3), which is inhibited by serine-phosphorylation, is
involved in the neuropathology of Alzheimer's disease (AD). We tested if the two therapeutic …

Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a
disease modifying treatment. As increasing evidence has suggested a role for glycogen …

J. Neurochem.(2008) 104, 1433–1439. Abstract Glycogen synthase kinase 3 (GSK3) is a
constitutively active, proline‐directed serine/threonine kinase that plays a part in a number of …

Abnormalities in molecular signalling have been implicated in neurodegeneration. It is
emerging that glycogen synthase kinase‐3 (GSK‐3) is a key signalling molecule that …

A pivotal role has emerged for glycogen synthase kinase‐3 (GSK3) as an important
contributor to Alzheimer′ s disease pathology. Evidence for the involvement of GSK3 in …

For over fifty years lithium has been a fundamental component of therapy for patients with
bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal …

Accumulating evidence suggests that glycogen synthase kinase 3 (GSK-3) is a
multifunctional kinase implicated in Alzheimer's disease (AD). However, the synaptic actions …

Introduction: Glycogen synthase kinase-3 (GSK-3) is recognized as a crucial player in many
cellular functions and its activity is tightly controlled by complex mechanisms that are each …

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder with
dementia, accounting for approximately 70% of the all cases. Currently, 5.8 million people in …